ES2145772T3 - Uso de un complejo de ibuprofeno-beta-ciclodextrina para administracion oral. - Google Patents

Uso de un complejo de ibuprofeno-beta-ciclodextrina para administracion oral.

Info

Publication number
ES2145772T3
ES2145772T3 ES93907987T ES93907987T ES2145772T3 ES 2145772 T3 ES2145772 T3 ES 2145772T3 ES 93907987 T ES93907987 T ES 93907987T ES 93907987 T ES93907987 T ES 93907987T ES 2145772 T3 ES2145772 T3 ES 2145772T3
Authority
ES
Spain
Prior art keywords
ibuprofen
beta
pct
cyclodextrin
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93907987T
Other languages
English (en)
Inventor
Timothy James Grattan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Application granted granted Critical
Publication of ES2145772T3 publication Critical patent/ES2145772T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE PRESENTA UN COMPLEJO DE IBUPROFEN-(BETA)-CICLODEXTRINA PARA SU CONSUMO ORAL EN UNA SOLUCION QUE COMPRENDA AGUA CALIENTE, QUE SE OBTIENE MEDIANTE CRISTALIZACION A PARTIR DE UNA SOLUCION ACUOSA.
ES93907987T 1992-04-10 1993-04-02 Uso de un complejo de ibuprofeno-beta-ciclodextrina para administracion oral. Expired - Lifetime ES2145772T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929207990A GB9207990D0 (en) 1992-04-10 1992-04-10 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
ES2145772T3 true ES2145772T3 (es) 2000-07-16

Family

ID=10713877

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93907987T Expired - Lifetime ES2145772T3 (es) 1992-04-10 1993-04-02 Uso de un complejo de ibuprofeno-beta-ciclodextrina para administracion oral.

Country Status (12)

Country Link
US (1) US5597583A (es)
EP (1) EP0633787B1 (es)
JP (1) JPH07505645A (es)
KR (1) KR950700762A (es)
AT (1) ATE190505T1 (es)
AU (1) AU667095B2 (es)
CA (1) CA2117762A1 (es)
DE (1) DE69328087T2 (es)
ES (1) ES2145772T3 (es)
GB (1) GB9207990D0 (es)
NZ (1) NZ251393A (es)
WO (1) WO1993020850A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9507768A (pt) * 1994-05-27 1997-09-02 Farmarc Nederland Bv Composição farmacêutica
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
IT1301966B1 (it) 1998-07-30 2000-07-20 Zambon Spa Composizioni farmaceutiche ad attivita' analgesica
US6211246B1 (en) * 1999-06-10 2001-04-03 Mcneil-Ppc, Inc. Rapidly absorbed liquid compositions
ES2171110B1 (es) * 2000-03-03 2003-06-16 Aplicaciones Farmacodinamicas Composicion farmaceutica a base de ibuprofeno y procedimiento para su preparacion.
NZ524348A (en) * 2000-08-02 2004-07-30 Malope Company Ltd Diagnosis and treatment of non-ulcer dyspepsia based on dysfunction in the corticotropin releasing hormone (CRH) receptor and repsonse to ACTH
AU2002327418A1 (en) * 2001-08-01 2003-02-17 Bristol-Myers Squibb Company Taste masking composition
KR100567131B1 (ko) * 2004-01-05 2006-04-05 신일제약주식회사 쓴맛을 차폐한 아르기닌 함유 이부프로펜 경구투여 액상조성물
AU2006312119B2 (en) * 2005-11-02 2010-04-29 Teikoku Pharma Usa, Inc. Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same
US20070207206A1 (en) * 2006-03-02 2007-09-06 Rice Bronwyn C Chewable pain formula
RU2437657C2 (ru) * 2006-03-16 2011-12-27 Новартис Аг Твердая лекарственная форма, содержащая активный агент с маскированным вкусом
EP2253329B1 (en) * 2009-04-27 2016-09-21 Laboratorio de Aplicaciones Farmacodinamicas, S.A. Ibuprofen lysinate oral suspension
JP5977672B2 (ja) * 2009-04-27 2016-08-24 ラボラトリオ デ アプリカシオネス ファルマコディナミカス，エセ．アー．Ｌａｂｏｒａｔｏｒｉｏ Ｄｅ Ａｐｌｉｃａｃｉｏｎｅｓ Ｆａｒｍａｃｏｄｉｎａｍｉｃａｓ，Ｓ．Ａ． イブプロフェンリシナートの経口投与用の懸濁液
CN114588107B (zh) * 2022-04-06 2023-04-18 河北一品生物医药有限公司 一种布洛芬赖氨酸盐注射液及其制备方法
EP4516290A1 (en) 2023-08-31 2025-03-05 Grindeks, A Joint Stock Company Pharmaceutical composition of combination of a non-steroidal anti-inflammatory drugs (nsaids) and decongestant in the form of a powder or granules for preparing a hot drink

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43290B (en) * 1986-11-13 1989-06-30 Lek Tovarna Farmacevtskih Process for preparing inclusioned complex of ibuproxane with beta-cyclodextrine
CA1298290C (en) * 1987-01-09 1992-03-31 Herand M. Markarian Solution ibuprofen complexes, compositions and processes for preparing the same
GB8813682D0 (en) * 1988-06-09 1988-07-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
US5024997A (en) * 1990-06-22 1991-06-18 American Home Products Corporation Palatable ibuprofen solutions
DE4038314A1 (de) * 1990-11-30 1992-06-04 Puetter Medice Chem Pharm Komplexe des aktiven enantiomers des ibuprofens mit cyclodextrin

Also Published As

Publication number Publication date
EP0633787B1 (en) 2000-03-15
WO1993020850A1 (en) 1993-10-28
DE69328087T2 (de) 2000-08-24
US5597583A (en) 1997-01-28
JPH07505645A (ja) 1995-06-22
GB9207990D0 (en) 1992-05-27
CA2117762A1 (en) 1993-10-28
HK1012260A1 (en) 1999-07-30
DE69328087D1 (de) 2000-04-20
KR950700762A (ko) 1995-02-20
ATE190505T1 (de) 2000-04-15
AU3898793A (en) 1993-11-18
EP0633787A1 (en) 1995-01-18
NZ251393A (en) 1996-08-27
AU667095B2 (en) 1996-03-07

Similar Documents

Publication Publication Date Title
ES2145772T3 (es) Uso de un complejo de ibuprofeno-beta-ciclodextrina para administracion oral.
DK0652773T3 (da) Anvendelse af nor- og homo-galdesyrederivater somabsorptionsfremmende bestanddele i lægemidler
DE69408666D1 (de) Risperidon pamoate
DK0675956T3 (da) Nyt protein fra urin betegnet komponent B
ATE168886T1 (de) Abgabevorrichtung mit eingekapselten hilfsmitteln
ES2178651T3 (es) Compuestos carotenoides terapeuticos deispersables en agua.
DK455088D0 (da) Syntetiske receptoranaloger
MX9401406A (es) Agentes receptores de adenosina selectivos para intensificar el conocimiento.
CS9100438A2 (en) New derivative of beta-phenylisoserine, method of its preparation and its application
MX9205385A (es) Perhidro-1-h-pirido(1,2-a)piracinas 2-sustituidas neurolepticas.
ES2163001T3 (es) Nuevos derivados de borneol, procedimiento para su preparacion y su utilizacion farmaceutica.
ATE175971T1 (de) Wasserlösliche retinoide
DE69512087D1 (de) Monoazopigmente
SE9404438D0 (sv) New process
FI934977A0 (fi) Foerfarande foer att reducera elkfoerbrukningen i mikroprocessorbaserade,isynnerhet foer publika telefonstationer avsedda anordningar
GR3023147T3 (en) New triazoloquinazolines, their production and their use.
ATE221068T1 (de) Anellierte beta-carboline
KR920004437U (ko) 오 · 페수용 산기관
DE69407180D1 (de) Fluoro-nukleosid-reinigung

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 633787

Country of ref document: ES